Drug-induced lupus erythematosus

Area of Science:

• Dermatology
• Immunology
• Rheumatology

Background:

• Drug-induced lupus erythematosus (DI-LE) shares clinical and serological features with idiopathic lupus.
• DI-LE is categorized into systemic, subacute cutaneous (SCLE), chronic cutaneous (CCLE), and tumidus forms.
• DI-SCLE is the predominant subtype of drug-induced cutaneous lupus.

Purpose of the Study:

• To investigate the distinct clinical features of drug-induced subacute cutaneous lupus erythematosus (DI-SCLE) compared to its idiopathic counterpart.
• To identify diagnostic hallmarks for DI-SCLE.

Main Methods:

• Comparative analysis of clinical manifestations and immunopathological findings in DI-LE and idiopathic lupus.
• Review of histopathological data for DI-SCLE and other DI-LE variants.

Main Results:

• DI-SCLE frequently presents with widespread annular-polycyclic lesions, often involving the lower legs, unlike idiopathic SCLE.
• Malar rash, bullous, erythema multiforme-like, and vasculitic manifestations are characteristic of DI-SCLE.
• Histopathology, including lichenoid interface dermatitis and tissue eosinophilia, is not a reliable differentiator for DI-SCLE.

Conclusions:

• DI-SCLE exhibits distinct clinical features, notably malar rash and specific cutaneous manifestations, differentiating it from idiopathic SCLE.
• Histological findings are not diagnostic for DI-SCLE.
• Management of DI-LE primarily involves drug cessation, with immunomodulatory agents reserved for refractory cases.